The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data...

The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data...

FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) plus chemotherapy as treatment for adult...

– Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 – – EU...

Roche announced that the European Medicines Agency (EMA) has validated and initiated review of the marketing authorisation application (MAA) for...

The CAPItello─290 phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or...

AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular...

Zegalogue (dasiglucagon, Zealand Pharma) has been recommended by the European Medicines Agency (EMA) for the treatment of severe hypoglycemia in...

A discovery by researchers at the University of British Columbia, Canada, promises to improve care for patients with endometrial cancer, the most...

Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with...